Results 171 to 180 of about 1,419,720 (263)

Mineralocorticoid receptor antagonists for the treatment of heart failure and kidney disease: a state-of-the-art review. [PDF]

Heart Fail Rev
Van Spall HGC, Vardeny O.
europepmc   +1 more source

GLP‐1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications

Journal of Internal Medicine, Volume 300, Issue 6, Page 758-778, December 2026.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists provide benefits in weight reduction, glycaemic control in Type 2 diabetes, and cardiovascular and renal outcomes. Their widespread use has given rise to concerns regarding rare but potentially serious adverse events.
Peter Ueda
wiley   +1 more source

Mineralocorticoid receptor antagonists: Efficacy and safety in chronic kidney disease. [PDF]

Diabetes Obes Metab
Mottl AK, Khunti K, Mathieu C.
europepmc   +1 more source

Subcutaneous Furosemide for Ambulatory Decongestion in Heart Failure: Outcomes From a High‐Risk Real‐World Cohort

Clinical Cardiology, Volume 49, Issue 11, November 2026.
In 49 high‐risk ambulatory heart failure patients with persistent congestion despite oral diuretics, subcutaneous furosemide was well tolerated, with a 20.4% 30‐day HF hospitalization rate. Among non‐hospitalized patients, the median NYHA class improved from III to II, and the weight decreased by 2.6 kg.
Omar Jafar, Ann Harper, Angela Toepp, Amin Yehya   +3 more
wiley   +1 more source

Non-steroidal mineralocorticoid receptor antagonists in non-diabetic kidney disease: a narrative review of mechanisms and clinical advances. [PDF]

BMC Nephrol
Luo F, Hu J, Fang H, Li X, Zhu C, Bao Z.
europepmc   +1 more source

In Silico Clinical Trials in Drug Development: Virtual Patients, Applications, and Regulatory Convergence

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1181-1194, November 2026.
Conventional clinical trials remain the benchmark for evaluating therapeutic safety and efficacy, yet they are constrained by escalating costs, withdrawal over the extended follow‐up periods, recruitment difficulties, ethical limits, and a restricted ability to characterize heterogeneous populations.
Maximilian Balmus, Sheng‐Ya Wang, Edward W. G. Ashton, Rosie K. Barrows, Molly Monks, Yuzhang Ge, Arthur Lefebvre, Steven A. Niederer   +7 more
wiley   +1 more source

Nonsteroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Mechanistic Basis, Clinical Evidence, and Therapeutic Integration. [PDF]

Drugs Drug Candidates
Al-Horani RA, Goyal N.
europepmc   +1 more source

Toward a digital urinary biopsy for early risk stratification in diabetic kidney disease: Anchoring shed cells, vesicles, and cell‐free DNA to spatial kidney cell states

Clinical and Translational Medicine, Volume 16, Issue 11, November 2026.
In diabetic kidney disease, one urine specimen carries shed cells, extracellular vesicles and cell‐free DNA released along the whole nephron. Reading all three against spatial kidney atlases is proposed as a testable route to cell‐resolved, non‐invasive risk stratification, and the clinical outputs shown are not yet demonstrated.
Juan Wu, Ping Sheng, Ying Lu, Ke Chen
wiley   +1 more source

Fermented Noni Juice Supplementation Attenuates Heart Failure Development in Mice: Involvement of the Pentose Phosphate Pathway

Food Frontiers, Volume 7, Issue 6, November 2026.
ABSTRACT Morinda citrifolia L., commonly known as Noni, is a traditional medicinal plant that has long been utilized in various cultures for its anti‐inflammatory and antioxidant properties. Heart failure (HF) is a significant and growing public health concern worldwide that is characterized by substantial morbidity, mortality, and healthcare costs ...
Min Zhang, Xia Guan, Ruize Lu, Zhangxin Yu, Xuanjia Chen, Jingyao Xu, Guangying Chen, Haiying Zhang, Yan Liu   +8 more
wiley   +1 more source

PRO/CON debate: nonsteroidal versus steroidal mineralocorticoid receptor antagonists in chronic kidney disease: progress, pragmatism, and remaining uncertainties. [PDF]

Clin Kidney J
Agarwal R, Vogt L, Floege J, Zoccali C.
europepmc   +1 more source